Emerging targeted combinations in the management of breast cancer

Breast Cancer: Targets and Therapy

Volumn 5, Issue , 2013, Pages 61-72

  Lee, Rebecca J ^a   Armstrong, Anne C ^a   Wardley, Andrew M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Receptor; Targeted therapy; Tyrosine kinase

Indexed keywords

AFLIBERCEPT; ANASTROZOLE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FULVESTRANT; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; LETROZOLE; NERATINIB; OLAPARIB; PERTUZUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VANDETANIB; VATALANIB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84889256571     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S26771     Document Type: Review

References (77)

1. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513-516.
2. Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist. 2009;14(4):320-368.
4. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
5. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Paper presented at: ASCO Annual Meeting Proceedings Part I 2007 San Francisco.
6. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29-36.
7. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
8. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23(11):2534-2543.
9. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun. 2000;277(3):757-763.
10. Gianni L, Lladó A, Bianchi G, et al. Open-label, Phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7):1131-1137.
11. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138-1144.
12. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
13. Swain SM, Kim SB, Cortes J, et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Research. 2012;72(24 Suppl 3):abstract P5-18-26.
14. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Research. 2008;68(22):9280-9290.
15. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698-2704.
16. Krop IE, LoRusso P, Miller KD, et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30(26):3234-3241.
17. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
18. Diéras V, Harbeck N, Budd GT, et al. Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies. Cancer Research. 2012;72(24 Suppl 3):P5-18-06.
19. Ellis P, Barrios C, Im Y, Patre M, Branle F, Perez E. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol. 2011;29(Suppl; abstr TPS102).
20. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28(20):3366-3379.
21. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005;23(23):5323-5333.
22. Robertson J, Gutteridge E, Cheung K, Owers R. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol. 2003;22(abstr 23).
23. Albain K, Elledge R, Gradishar WJ, Natale RB. Open-label, phase II, multicenter trial of ZD 1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Research And Treatment. 2002;76(S33):(Suppl 1; abstr 20).
24. von Minckwitz G, Jonat W, Fasching P, et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;89(2):165-172.
25. Ciardiello F, Troiani T, Caputo F, et al. Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer. Br J Cancer. 2006;94(11):1604-1609.
26. Engebraaten O, Edvardsen H, Løkkevik E, et al. Gefitinib in combination with weekly docetaxel in patients with metastatic breast cancer caused unexpected toxicity: results from a randomized Phase II clinical trial. ISRN Oncology. 2012;2012:8.
27. Smith IE, Walsh G, Skene A, et al. A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25(25):3816-3822.
28. Carlson R W, O'Neill A, Vidaurre T, Gomez HL, Badve S. Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol. 2009;27(15S):1013.
29. Twelves C, Trigo JM, Jones R, et al. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer. 2008;44(3):419-426.
30. Dickler MN, Rugo HS, Eberle CA, et al. A phase ii trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008;14(23):7878-7883.
31. Kaur H, Silverman P, Singh D, Cooper BW, Fu P, Krishnamurthi S. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol. 2006;24(18S):10623.
32. Montagna E, Cancello G, Bagnardi V, et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer. 2012;12(3):207-214.
33. Graham DL, Hillman DW, Hobday TJ, et al. N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). J Clin Oncol. 2005;23(16S):644.
34. Hobday TJ, Stella PJ, Fitch TR, et al. N0436: a phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol. 2008;26(Suppl):abstr 1081.
35. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase ii study of cetuximab in combination with carboplatin in Stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615-2623.
36. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2006;355(26):2733-2743.
37. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 379(9816):633-640.
38. Gelmon KA, Boyle F, Kaufman B, et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol. 2012;30(Suppl 15):abstract LBA671.
39. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. Dec 2008;112(3):533-543.
40. Lin NU, Diéras V, Paul D, et al. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer Research. February 15, 2009;15(4):1452-1459.
41. Pivot X, Semiglazov V, Żurawski B, et al. CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastuzumab plus Capecitabine (TC). Annals of Oncology. 2012;23(Suppl 9):Abstract LBA11.
42. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301-1307.
43. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441(7092):424-430.
44. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2008;11(3):63-76.
45. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO Study. J Clin Oncol. 2012;30(22):2718-2724.
46. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630-2637.
47. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
48. Piccart-Gebhart MJ, Noguchi S, Pritchard KI, et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. J Clin Oncol. 2012;30(Suppl):abstr 559.
49. Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013;31(2):195-202.
50. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011;16(Suppl 1):12-19.
51. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research. 2008;68(15):6084-6091.
52. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer. 2006;13(2):137-144.
53. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research. 2001;61(1):131-137.
54. Dalenc F, Doisneau-Sixou SF, Allal BC, et al. Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin Cancer Res. 2010;16(4):1264-1271.
55. Li T, Guo M, Gradishar W, et al. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012;134(1):345-352.
56. Li T, Christos PJ, Sparano JA, et al. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann Oncol. 2009;20(4):642-647.
57. Johnston S, Semiglazov V, Manikhas G, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. 2008;110(2):327-335.
58. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
59. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376(9737):235-244.
60. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29(Suppl 15):abstr 1007.
61. Relf M, LeJeune S, Scott PAE, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57(5):963-969.
62. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779-1802.
63. Miles DW, Chan A, Dirix LY, et al. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2010;28(20):3239-3247.
64. Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. J Clin Oncol. 2005;23(4):792-799.
65. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252-1260.
66. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
67. Brufsky A, Hurvitz SA, Perez EA, et al. Final overall survival (OS) and safety analyses of RIBBON-2, a randomised phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second line chemotherapy (CT) for HER2-negative-BEV-naive metastatic breast cancer (MBC). J Clin Oncol. 2012;30(Suppl 27):abstr 100.
68. Cameron D, Brown J, Dent R, et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Research. 2012;72(24, Suppl 3). Available from: http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S6-5?rss=1. Accessed May 20, 2013.
69. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009;27(1):11-15.
70. Baselga J, Segalla JGM, Roché H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012;30(13):1484-1491.
71. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121(1):121-131.
72. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol. 2010;28(Suppl):abstr 18.
73. Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30(9):921-929.
74. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2005;11(9):3369-3376.
75. Boér K, Láng I, Llombart-Cussac A, et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II study. Invest New Drugs. 2012;30(2):681-687.
76. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178-2189.
77. US National Institutes of Health. PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00216047. Accessed June 23rd, 2013.